217 related articles for article (PubMed ID: 28635330)
21. Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging.
Corraliza-Gomez M; Bermejo T; Lilue J; Rodriguez-Iglesias N; Valero J; Cozar-Castellano I; Arranz E; Sanchez D; Ganfornina MD
J Neuroinflammation; 2023 Oct; 20(1):233. PubMed ID: 37817156
[TBL] [Abstract][Full Text] [Related]
22. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.
Maianti JP; McFedries A; Foda ZH; Kleiner RE; Du XQ; Leissring MA; Tang WJ; Charron MJ; Seeliger MA; Saghatelian A; Liu DR
Nature; 2014 Jul; 511(7507):94-8. PubMed ID: 24847884
[TBL] [Abstract][Full Text] [Related]
23. Redox regulation of insulin degradation by insulin-degrading enzyme.
Cordes CM; Bennett RG; Siford GL; Hamel FG
PLoS One; 2011 Mar; 6(3):e18138. PubMed ID: 21448434
[TBL] [Abstract][Full Text] [Related]
24. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease.
Edland SD
J Mol Neurosci; 2004; 23(3):213-7. PubMed ID: 15181249
[TBL] [Abstract][Full Text] [Related]
25. Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo.
Durham TB; Toth JL; Klimkowski VJ; Cao JX; Siesky AM; Alexander-Chacko J; Wu GY; Dixon JT; McGee JE; Wang Y; Guo SY; Cavitt RN; Schindler J; Thibodeaux SJ; Calvert NA; Coghlan MJ; Sindelar DK; Christe M; Kiselyov VV; Michael MD; Sloop KW
J Biol Chem; 2015 Aug; 290(33):20044-59. PubMed ID: 26085101
[TBL] [Abstract][Full Text] [Related]
26. Identification and functional characterization of a putative IDE, C28F5.4 (ceIDE-1), in Caenorhabditis elegans: Implications for Alzheimer's disease.
Haque R; Nazir A
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2454-2462. PubMed ID: 27443962
[TBL] [Abstract][Full Text] [Related]
27. Proteasome Activity Is Affected by Fluctuations in Insulin-Degrading Enzyme Distribution.
Sbardella D; Tundo GR; Sciandra F; Bozzi M; Gioia M; Ciaccio C; Tarantino U; Brancaccio A; Coletta M; Marini S
PLoS One; 2015; 10(7):e0132455. PubMed ID: 26186340
[TBL] [Abstract][Full Text] [Related]
28. Non-covalent interaction of ubiquitin with insulin-degrading enzyme.
Saric T; Müller D; Seitz HJ; Pavelic K
Mol Cell Endocrinol; 2003 Jun; 204(1-2):11-20. PubMed ID: 12850277
[TBL] [Abstract][Full Text] [Related]
29. PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Du J; Zhang L; Liu S; Zhang C; Huang X; Li J; Zhao N; Wang Z
Biochem Biophys Res Commun; 2009 Jun; 383(4):485-90. PubMed ID: 19383491
[TBL] [Abstract][Full Text] [Related]
30. Identification of indole-based activators of insulin degrading enzyme.
Kraupner N; Dinh CP; Wen X; Landry V; Herledan A; Leroux F; Bosc D; Charton J; Maillard C; Warenghem S; Duplan I; Piveteau C; Hennuyer N; Staels B; Deprez B; Deprez-Poulain R
Eur J Med Chem; 2022 Jan; 228():113982. PubMed ID: 34815130
[TBL] [Abstract][Full Text] [Related]
31. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
Shen Y; Joachimiak A; Rosner MR; Tang WJ
Nature; 2006 Oct; 443(7113):870-4. PubMed ID: 17051221
[TBL] [Abstract][Full Text] [Related]
32. Correlations between insulin-degrading enzyme and metabolic markers in patients diagnosed with type 2 diabetes, Alzheimer's disease, and healthy controls: a comparative study.
Kullenberg H; Rossen J; Johansson UB; Hagströmer M; Nyström T; Kumlin M; Svedberg MM
Endocrine; 2024 May; 84(2):450-458. PubMed ID: 37980298
[TBL] [Abstract][Full Text] [Related]
33. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria.
Leissring MA; Farris W; Wu X; Christodoulou DC; Haigis MC; Guarente L; Selkoe DJ
Biochem J; 2004 Nov; 383(Pt. 3):439-46. PubMed ID: 15285718
[TBL] [Abstract][Full Text] [Related]
34. Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Tsuda M; Kobayashi T; Matsuo T; Aigaki T
FEBS Lett; 2010 Jul; 584(13):2916-20. PubMed ID: 20493190
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.
Azam MS; Wahiduzzaman M; Reyad-Ul-Ferdous M; Islam MN; Roy M
Pharm Res; 2022 Apr; 39(4):611-629. PubMed ID: 35378698
[TBL] [Abstract][Full Text] [Related]
36. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families.
Kim M; Hersh LB; Leissring MA; Ingelsson M; Matsui T; Farris W; Lu A; Hyman BT; Selkoe DJ; Bertram L; Tanzi RE
J Biol Chem; 2007 Mar; 282(11):7825-32. PubMed ID: 17244626
[TBL] [Abstract][Full Text] [Related]
37. Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme.
Adamek RN; Suire CN; Stokes RW; Brizuela MK; Cohen SM; Leissring MA
ChemMedChem; 2021 Jun; 16(11):1775-1787. PubMed ID: 33686743
[TBL] [Abstract][Full Text] [Related]
38. Ubiquitin is a novel substrate for human insulin-degrading enzyme.
Ralat LA; Kalas V; Zheng Z; Goldman RD; Sosnick TR; Tang WJ
J Mol Biol; 2011 Feb; 406(3):454-66. PubMed ID: 21185309
[TBL] [Abstract][Full Text] [Related]
39. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme.
Bennett RG; Fawcett J; Kruer MC; Duckworth WC; Hamel FG
J Endocrinol; 2003 Jun; 177(3):399-405. PubMed ID: 12773120
[TBL] [Abstract][Full Text] [Related]
40. [Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease].
Leal MC; Fernandez Gamba A; Morelli L; Castaño EM
Medicina (B Aires); 2009; 69(4):466-72. PubMed ID: 19770104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
